Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Infusion-related Costs for HyQvia Compared to Hizentra in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Neuromuscular and Clinical Neurophysiology (EMG)
P9 - Poster Session 9 (8:00 AM-9:00 AM)
CIDP is a rare autoimmune disease of the peripheral nervous system, resulting in symmetric weakness and impaired sensation in the limbs. Standard of care typically includes corticosteroids, plasma exchange, or intravenous Ig therapy, but additional treatments are needed to improve adherence, convenience, and tolerability. fSCIG-10%, a facilitated subcutaneous Ig therapy, is being evaluated for CIDP maintenance treatment and requires less-frequent injections (every 4 weeks) compared with weekly-administered SCIG-20%. 
To compare infusion-related costs for hypothetical US adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) receiving maintenance therapy with HyQvia (Immune Globulin [Ig] Infusion 10% [Human] with Recombinant Human Hyaluronidase; fSCIG-10%) versus Hizentra (Ig Subcutaneous [Human], 20% Liquid; SCIG-20%).
Using a US commercial payers’ perspective over a 1-year time horizon, an economic model evaluated per-person infusion-related costs for adults receiving maintenance therapy with fSCIG-10% or SCIG-20%. Parameter and infusion-related cost data were identified via literature review and ad hoc searches. Similar resource-use estimates were used for both treatment groups; differences were in frequency of dosing, at-home vs infusion center administration, and nursing visits for at-home administration.
Total infusion-related costs were $4808 for fSCIG-10% and $6484 for SCIG-20%. Infusion center visits contributed most to costs (fSCIG-10%: $3345; SCIG-20%: $4295). Additional annual per-person infusion-related costs included (fSCIG-10% vs SCIG-20%): self-infusion pump and materials ($1017 vs $1017), nurse hours ($446 vs $1128), and manual push infusion and materials ($0 vs $44). A scenario analysis demonstrated that fSCIG-10% saved cost if ≥53% of individuals received fSCIG-10% at home.
Treatment with fSCIG-10% resulted in total annual savings of $1676 per person with CIDP. Savings are attributed to less-frequent administration, resulting in fewer per-person infusion costs and nursing hours.
Faisal Riaz, MD
Dr. Riaz has received personal compensation for serving as an employee of Takeda Pharmaceuticals. Dr. Riaz has stock in Takeda.
Nikhil Khandelwal No disclosure on file
Sepehr Farahbakhshian (Takeda Pharmaceutical Company Limited) No disclosure on file
Anne Loos (Wickenstones Ltd) No disclosure on file
Busayo Soyemi (wickenstones) No disclosure on file
Sam Taylor (Wickenstones Ltd.) No disclosure on file